1
|
Serebruany VL, Malinin A, Eisert C, Ong S. AGI-1067, a novel vascular protectant, anti-inflammatory drug and mild antiplatelet agent for treatment of atherosclerosis. Expert Rev Cardiovasc Ther 2014; 5:635-41. [PMID: 17605642 DOI: 10.1586/14779072.5.4.635] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Oxidation-sensitive signals play an important role in platelet activation. AGI-1067 is a novel, phenolic, intra- and extracellular antioxidant that inhibits the expression of a number of proinflammatory genes involved in atherosclerosis. AGI-1067 is the metabolically stable monosuccinic acid ester of probucol, and a potent phenolic antioxidant representing a novel class of orally bioavailable compounds termed vascular protectants. AGI-1067 exhibits antioxidant activity equipotent to probucol. In addition, animal studies have demonstrated dual pharmacological activities of AGI-1067: the ability to block the expression of oxidation-sensitive inflammatory genes including genes that code for vascular cell adhesion molecule-1 and monocyte chemotactic protein-1. Importantly, AGI-1067 also exhibits mild antiplatelet properties inhibiting surface expression of various key platelet receptors, the formation of platelet monocyte microparticles and PAR-1 thrombin receptors. AGI-1067 is currently being tested in the late trials, and if proven to improve clinical outcomes (ARISE trial), the drug will ultimately be used in patients with different manifestations of atherosclerosis and atherothrombosis.
Collapse
Affiliation(s)
- Victor L Serebruany
- HeartDrug Research Laboratories, Osler Medical Center, 7600 Osler Drive, Suite 307, Towson, MD 21204, USA.
| | | | | | | |
Collapse
|
2
|
Hoekstra M, Berkel TJCV, Eck MV. Scavenger receptor BI: A multi-purpose player in cholesterol and steroid metabolism. World J Gastroenterol 2010; 16:5916-24. [PMID: 21157967 PMCID: PMC3007109 DOI: 10.3748/wjg.v16.i47.5916] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Scavenger receptor class B type I (SR-BI) is an important member of the scavenger receptor family of integral membrane glycoproteins. This review highlights studies in SR-BI knockout mice, which concern the role of SR-BI in cholesterol and steroid metabolism. SR-BI in hepatocytes is the sole molecule involved in selective uptake of cholesteryl esters from high-density lipoprotein (HDL). SR-BI plays a physiological role in binding and uptake of native apolipoprotein B (apoB)-containing lipoproteins by hepatocytes, which identifies SR-BI as a multi-purpose player in lipid uptake from the blood circulation into hepatocytes in mice. In adrenocortical cells, SR-BI mediates the selective uptake of HDL-cholesteryl esters, which is efficiently coupled to the synthesis of glucocorticoids (i.e. corticosterone). SR-BI knockout mice suffer from adrenal glucocorticoid insufficiency, which suggests that functional SR-BI protein is necessary for optimal adrenal steroidogenesis in mice. SR-BI in macrophages plays a dual role in cholesterol metabolism as it is able to take up cholesterol associated with HDL and apoB-containing lipoproteins and can possibly facilitate cholesterol efflux to HDL. Absence of SR-BI is associated with thrombocytopenia and altered thrombosis susceptibility, which suggests a novel role for SR-BI in regulating platelet number and function in mice. Transgenic expression of cholesteryl ester transfer protein in humanized SR-BI knockout mice normalizes hepatic delivery of HDL-cholesteryl esters. However, other pathologies associated with SR-BI deficiency, i.e. increased atherosclerosis susceptibility, adrenal glucocorticoid insufficiency, and impaired platelet function are not normalized, which suggests an important role for SR-BI in cholesterol and steroid metabolism in man. In conclusion, generation of SR-BI knockout mice has significantly contributed to our knowledge of the physiological role of SR-BI. Studies using these mice have identified SR-BI as a multi-purpose player in cholesterol and steroid metabolism because it has distinct roles in reverse cholesterol transport, adrenal steroidogenesis, and platelet function.
Collapse
|
3
|
Zhao B, Dierichs R, Ahonen-Sann R. Low Concentration of LDL Enhances Platelet Reactivity In Vitro— a Morphological Study. Platelets 2009; 4:41-4. [DOI: 10.3109/09537109309013194] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
4
|
Naran NH, Chetty N. The in vitro effect of ridogrel on platelet function in normocholesterolaemic and familial hypercholesterolaemic type IIa subjects. Thromb Res 1997; 88:399-407. [PMID: 9556227 DOI: 10.1016/s0049-3848(97)00271-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Platelets from familial hypercholesterolaemia type IIa patients are hyperreactive and produce increased amounts of thromboxane A2. These modifications of platelet function may play an important role in the occurrence of premature atherosclerosis. One approach to the prevention of the thromboembolic complications of atherosclerosis is the use of antiplatelet agents which depress platelet function. Ridogrel, a combined thromboxane synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor blocker inhibits platelet aggregation. This study was designed to investigate the in vitro effect of ridogrel on platelet function in normocholesterolaemic and familial hypercholesterolaemia type IIa subjects. In citrated platelet rich plasma ridogrel significantly inhibited platelet aggregation and thromboxane A2 production in response to collagen, ADP and arachidonic acid stimulation. In washed platelets ridogrel significantly decreased aggregation and serotonin release. Ridogrel significantly increased cAMP levels in response to thrombin stimulation. In conclusion, ridogrel at low concentrations significantly inhibited the in vitro function of platelets in a dose dependant manner in both normocholesterolaemic subjects and familial hypercholesterolaemia IIa subjects.
Collapse
Affiliation(s)
- N H Naran
- Department of Haematology, School of Pathology of the South African Institute for Medical Research, and the University of the Witwatersrand, Johannesburg, Gauteng, Republic of South Africa
| | | |
Collapse
|
5
|
Menys VC, Bhatnagar D, Mackness MI, Durrington PN. Spontaneous platelet aggregation in whole blood is increased in non-insulin-dependent diabetes mellitus and in female but not male patients with primary dyslipidemia. Atherosclerosis 1995; 112:115-22. [PMID: 7772062 DOI: 10.1016/0021-9150(94)05417-h] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Increased platelet aggregability has been shown in hypercholesterolemia, and stirring-induced spontaneous aggregation in whole blood is increased in insulin-dependent diabetes mellitus (DM). We have determined spontaneous aggregation in citrated (10 mM) whole blood, from 27 primary dyslipidemic patients (DYS; 14F, 13M), 16 male non-insulin-dependent DM (NIDDM) patients, and 17 normolipidemic controls (N; 6F, 11M), using platelet counting to quantify aggregation. Spontaneous aggregation was significantly higher, both in the female DYS group (median 30% [interquartile range 25,50], P < 0.005) and the NIDDM group (33% [25,41], P < 0.005), than in the N group (17% [12,27]), but did not differ significantly in the male DYS group (23% [10,33]). Similar results were obtained in the presence of indomethacin (25 mumol/l) to prevent artefactual thromboxane (TX) A2 formation, indicating that increased spontaneous aggregation was TXA2-independent. Interestingly, increased spontaneous aggregation appeared to be independent of serum cholesterol and triglyceride concentrations, as well as age and sex per se. We conclude that spontaneous platelet aggregation was increased both in female primary dyslipidemic patients and NIDDM patients, but not in male DYS patients. The clinical significance of increased spontaneous platelet aggregability is that it may favour shear-induced aggregation which may occur at critical arterial stenoses in vivo leading to thrombus formation.
Collapse
Affiliation(s)
- V C Menys
- Department of Biological Sciences, Manchester Metropolitan University, UK
| | | | | | | |
Collapse
|
6
|
Bröijersén A, Eriksson M, Angelin B, Hjemdahl P. Gemfibrozil enhances platelet activity in patients with combined hyperlipoproteinemia. Arterioscler Thromb Vasc Biol 1995; 15:121-7. [PMID: 7749807 DOI: 10.1161/01.atv.15.1.121] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
A placebo-controlled crossover study was conducted to evaluate whether lipid-lowering with gemfibrozil (10 to 12 weeks) affects platelet function in vivo at rest and during mental stress in 21 men with combined hyperlipoproteinemia. Gemfibrozil lowered plasma triglycerides and total and VLDL cholesterol (P < .001 for all), whereas HDL cholesterol increased (P < .001). Gemfibrozil increased platelet counts by 18% (P < .001) and, according to filtragometry measurements, enhanced overall (means of rest and stress values) platelet aggregability in vivo (P = .014); this effect was more evident during mental stress (P = .027) than at rest (P = .18). Moreover, the urinary excretion of 11-dehydro-thromboxane-B2 was 54% higher during treatment with gemfibrozil (P < .001), whereas the excretion of beta-thromboglobulin in urine was unaltered. Plasma beta-thromboglobulin tended to be slightly elevated during active treatment (P = .15). Mental stress increased heart rate and catecholamine levels and elevated all cholesterol fractions (P < .01) and plasma beta-thromboglobulin (during placebo, P = .02), but platelet aggregability did not increase significantly. A positive correlation was found between 11-dehydrothromboxane-B2 excretion and LDL cholesterol levels during placebo (r = .62, P = .0057). In conclusion, gemfibrozil has beneficial effects on plasma lipoprotein levels but enhances several aspects of platelet activity in vivo and increases platelet counts. These changes might be prothrombotic and thus adverse for the hyperlipidemic patient. Primary preventive effects of gemfibrozil might be enhanced if a platelet inhibitor such as aspirin is administered with gemfibrozil.
Collapse
Affiliation(s)
- A Bröijersén
- Department of Clinical Pharmacology, Huddinge University Hospital, Stockholm, Sweden
| | | | | | | |
Collapse
|
7
|
Chetty N, Naran NH. Platelet hyperreactivity in hyperlipidaemia with specific reference to platelet lipids and fatty acid composition. Clin Chim Acta 1992; 213:1-13. [PMID: 1477981 DOI: 10.1016/0009-8981(92)90216-d] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Platelet function after thrombin stimulation, the fatty acid composition of individual phospholipids, and levels of lipid components (cholesterol, cholesterol ester, phospholipids and triglycerides) were determined in total membranes of platelets from hyperlipidaemic (HL) and control subjects. Platelet aggregation, thromboxane (TX) B2 production and serotonin release was significantly greater in HL patients than in controls. Levels of platelet cholesterol, total phospholipids, cholesterol ester and triglycerides, were significantly higher in the HL patients. Small differences between the two groups were observed for the phospholipid fatty acid patterns. However, levels of arachidonic acid (AA) were significantly higher in phosphatidylinositol (PI) of HL patients (40.01 +/- 6.59 mol%) as compared to the controls (31.52 +/- 9.91 mol%) (P = 0.002). The higher levels of AA in PI, which is considered a donor pool for eicosanoid synthesis, may be an additional mechanism for the well documented platelet hyperfunction and greater TXB2 production in hyperlipidaemic subjects.
Collapse
Affiliation(s)
- N Chetty
- Department of Haematology, School of Pathology, South African Institute for Medical Research, Johannesburg
| | | |
Collapse
|
8
|
Kochhar N, Kaul D. Molecular link between membrane cholesterol and Na+/H+ exchange within human platelets. FEBS Lett 1992; 299:19-22. [PMID: 1312031 DOI: 10.1016/0014-5793(92)80090-4] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Incubation of human platelets with cholesterol-poor, cholesterol-normal and cholesterol-rich liposomes revealed that: (i) acquisition or depletion of platelet membrane cholesterol was highly selective; (ii) variation in membrane cholesterol was highly selective. Variation in membrane cholesterol content (cholesterol-to-phospholipid molar ratio from 0.15-1.2) with respect to values found in unmodified normal platelets, was paralleled by the observed changes in amiloride-sensitive cytoplasmic pH, as well as phospholipase A2 activity. However, a decrease in cytoplasmic pH was accompanied by an increase in phospholipase A2 activity; (iii) membrane cholesterol-modulated changes in intra-platelet pH, as well as phospholipase A2 activity, was completely inhibited when platelets were pretreated with quinacrine (a specific phospholipase A2 inhibitor) before exposure to various types of liposomes. Although exposure of platelets (pretreated with amiloride) with various types of liposomes resulted in the inhibition of Na+/H+ exchange it had no noticeable effect upon the observed phospholipase A2 activity. Based upon these results we suggest that membrane cholesterol-modulated phospholipase A2 activity may be the basic mechanism responsible for the nature of Na+/H+ exchanger activity observed in cholesterol-enriched platelets, leading these platelets to a hypersensitized state.
Collapse
Affiliation(s)
- N Kochhar
- Department of Experimental Medicine, P.G.I.M.E.R., Chandigarh, India
| | | |
Collapse
|
9
|
Affiliation(s)
- C Rice-Evans
- Division of Biochemistry, UMDS-St Thomas's Campus, London, U.K
| | | |
Collapse
|
10
|
Katzman PL, Bose R, Walker S, Perry Y, Bolli P. Temperature-dependence of LDL binding and activation of human platelets. Thromb Res 1991; 64:503-8. [PMID: 1788835 DOI: 10.1016/0049-3848(91)90350-6] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
The effect of low density lipoprotein (LDL) on intracellular free calcium ion concentration ([Ca2+]i), taken as an index of the degree of platelet activation, was investigated in normal volunteers. At 37 degrees C LDL, in a dose of 20 micrograms of protein/ml, increased [Ca2+]i in all subjects tested (basal 57 +/- 11 to 113 +/- 19 nM). In contrast, when measurements were performed at 20 degrees C, no effect on [Ca2+]i was seen following LDL. Thrombin (0.2 U/ml) increased [Ca2+]i to 455 +/- 98 nM. When platelets had been exposed to LDL before thrombin stimulation, this increase was less pronounced (to 301 +/- 43 nM). Our finding of a temperature dependence of LDL induced increase in platelet [Ca2+]i supports the concept of a platelet-LDL receptor mediated mechanism. Furthermore, the lower thrombin response following LDL exposure suggests a LDL-thrombin interaction, possibly at the thrombin receptor level and/or calcium recruitment from the same stores.
Collapse
Affiliation(s)
- P L Katzman
- Department of Medicine, University of Manitoba, Winnipeg, Canada
| | | | | | | | | |
Collapse
|
11
|
Schick BP. Effect of diet-induced hypercholesterolemia on proteoglycan metabolism in guinea pig megakaryocytes and platelets. ARTERIOSCLEROSIS AND THROMBOSIS : A JOURNAL OF VASCULAR BIOLOGY 1991; 11:191-7. [PMID: 1987997 DOI: 10.1161/01.atv.11.1.191] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Proteoglycan metabolism was evaluated in megakaryocytes and platelets from guinea pigs fed a 1% cholesterol diet for 3 or 7 weeks. The animals were injected with a single dose of [35S]sulfate at the end of the feeding period, and megakaryocytes and platelets were isolated after 3 hours and then daily for 4 days thereafter. Proteoglycans were extracted from the cells of each animal and analyzed by ion-exchange chromatography, gel filtration, and electrophoresis. The maximal labeling of platelets occurred 2 days after [35S]sulfate injection as compared with 3 days in controls. A proteoglycan that eluted at Kav 0.2 from the Sepharose CL-6B column appeared 1 day after labeling. Additional proteoglycans of Kav 0.15 appeared at subsequent time points. The labeling profile for cholesterol-fed animals was unchanged from 2-4 days, unlike profiles from controls, which had exhibited a gradual increase in mean proteoglycan size. Thus, the progressive change in size of proteoglycans synthesized during normal megakaryocyte maturation was altered. The mean chain length of the proteoglycan-associated glycosaminoglycans from cholesterol-fed animals was increased relative to that of controls. In conjunction with the twofold increase in mean megakaryocyte size induced by cholesterol feeding in guinea pigs, the changes in proteoglycan synthesis suggest a state of stimulated megakaryocytopoiesis.
Collapse
Affiliation(s)
- B P Schick
- Cardeza Foundation for Hematologic Research, Jefferson Medical College of Thomas Jefferson University, Philadelphia, Pa
| |
Collapse
|
12
|
Bruckdorfer KR. The effects of plasma lipoproteins on platelet responsiveness and on platelet and vascular prostanoid synthesis. Prostaglandins Leukot Essent Fatty Acids 1989; 38:247-54. [PMID: 2561310 DOI: 10.1016/0952-3278(89)90128-2] [Citation(s) in RCA: 26] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Affiliation(s)
- K R Bruckdorfer
- Department of Biochemistry and Chemistry, Royal Free Hospital School of Medicine, London, UK
| |
Collapse
|
13
|
Abstract
Interactions between altered lipoproteins and platelets may be important in atherosclerosis lesion formation and thrombosis. The aims of this study were to compare the effects of oxidatively modified and native low density lipoproteins (LDL) and high density lipoproteins (HDL) on platelet responses in the presence and absence of other platelet agonists, and investigate the mechanism(s) by which lipoproteins influence platelet activation. We have shown that native and oxidatively modified lipoproteins differ importantly in their effects on platelets; oxidation renders lipoproteins more reactive to platelets. Native LDL promote aggregation of human platelets, enhance the mobilization of arachidonate from phospholipids, increase thromboxane B2 production, and decrease membrane fluidity. Oxidized LDL are more reactive than native LDL and alone cause aggregation. Native HDL inhibit platelet responses and increase membrane fluidity. Oxidized HDL promote aggregation and cause spontaneous aggregation. The enhanced platelet responses cannot be attributed to increased production of thromboxane A2 since cyclooxygenase inhibitors (aspirin, indomethacin) have little inhibitory effect. The data suggest that activation of platelets by lipoproteins results from changes in membrane fluidity. These observations shed new light on the potential role of altered lipoproteins in the pathogenesis of atherosclerosis and its complications.
Collapse
Affiliation(s)
- N G Ardlie
- Division of Clinical Sciences, John Curtin School of Medical Research, Australian National University, Canberra
| | | | | |
Collapse
|
14
|
Abstract
Enhanced platelet activity in patients with hypercholesterolemia and moderate hypertriglyceridemia can be attributed to increased LDL and VLDL and/or decreased HDL concentrations. In marked hypertriglyceridemia, where there is an accumulation of chylomicrons, platelet function is reduced. Treatment, whether by diet, medication, or plasmapheresis, that will result in a change in lipoprotein pattern is accompanied by a parallel change in platelet responsiveness. Incubation of lipoproteins with isolated platelets results in enhancement of platelet activation by LDL and VLDL and suppression of activity by HDL and chylomicrons. These findings have in vivo confirmation. They are even more pronounced and sometimes altered when the lipoproteins are derived from hyperlipidemic subjects. The effects of the lipoproteins on platelet activity appear to be dependent on lipoprotein composition and on factors such as cholesterol:protein ratio, apo C-III0:apo C-III2 ratio, apo B concentration, and triglyceride:protein ratio. The lipoproteins interact with platelets at specific receptor sites. Rapid change in platelet composition, particularly with regard to cholesterol, phospholipid, and fatty acid content, might ensue, with consequent alterations in membrane fluidity and enzyme activities and either suppression or activation of platelet function. This review has indicated that lipoproteins have a clear influence on platelet function. This interaction could be well of paramount importance in determining atherogenic risk.
Collapse
|